Skeletal imaging, radionuclide—Technetium Tc 99m oxidronate is indicated as a skeletal imaging agent in adults and children to delineate areas of abnormal osteogenesis, such as those that occur with metastatic bone disease, Paget's disease, arthritic disease, osteomyelitis, and fractures. Technetium Tc 99m oxidronate injection is a radiopharmaceutical. Exact mechanism is not known. It is generally accepted that technetium Tc 99m oxidronate localizes on the surface of hydroxyapatite crystals by a process termed chemisorption, with blood flow and/or blood concentration being most important in the delivery of the agent to sites of uptake. Visualization of osseous lesions is possible since skeletal uptake of technetium Tc 99m oxidronate is altered in areas of abnormal osteogenesis. Rapidly distributed in and cleared from blood after intravenous administration, with about half the dose normally accumulating in the skeleton within 3 to 4 hours after injection. May also locate within infarcted myocardial cells or other regions of soft tissue necrosis or calcification. Minimal uptake by soft-tissue organs, except calcified cartilage, blood vessels, and kidneys. TechneScan HDP exhibits its greatest affinity for areas of altered osteogenesis and actively metabolizing bone. Some hypersensitivity reactions, as well as nausea and vomiting, have been infrequently associated with Technetium Tc 99m Oxidronate.